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Objective. Anti–tumor necrosis factor (anti-TNF)
medications are effective in controlling chronic inflam-
matory diseases, but information about their use and
safety in pregnancy is limited. Consequently, anti-TNF
agents are often discontinued early in gestation. Cer-
tolizumab pegol (CZP), a PEGylated, Fc-free anti-TNF
agent approved for the treatment of rheumatic diseases
and/or Crohn’s disease, has minimal to no active placen-
tal transfer. This analysis was undertaken to evaluate
pregnancy outcomes in women receiving CZP, especially
those exposed during early pregnancy.
Methods. Prospective and retrospective data on
maternal CZP exposure were extracted from the UCB
Pharma safety database through March 6, 2017. Analysis
was limited to prospective reports to avoid potential bias
associated with retrospective submissions. The numbers
of live births, miscarriages, elective abortions, stillbirths,
and major congenital malformations were ascertained.
Results. Of 1,137 prospectively reported pregnan-
cies with maternal exposure to CZP, 528 (including 10 twin
pregnancies) had 538 known outcomes: 459 live births
(85.3%), 47 miscarriages (8.7%), 27 elective abortions
(5.0%), and 5 stillbirths (0.9%). There were 8 major con-
genital malformations (1.7%) among the 459 infants. First
trimester exposure occurred in 367 (81.2%) of 452 preg-
nancies resulting in 459 live births. Exposure during all 3
trimesters occurred in 201 (44.5%) of 452 pregnancies.
Conclusion. This analysis represents the largest
cohort of pregnant women exposed to an anti-TNF agent
for management of chronic inflammatory diseases. Analysis
of pregnancy outcomes does not indicate a teratogenic effect
of CZP, compared to the general population, nor an
increased risk of fetal death. The data are reassuring for
women of childbearing age considering treatment with CZP.
For women affected by chronic inflammatory dis-
eases, such as rheumatoid arthritis (RA), axial spondy-
loarthritis (SpA), psoriatic arthritis (PsA), and Crohn’s
disease (CD), disease onset, diagnosis, and initiation of
treatment increasingly overlap with peak reproductive age
(1,2). For many of these patients, disease activity during
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maternal health and ensure optimal fetal outcomes. Up to
half of pregnant patients with rheumatic diseases and the
majority of those with inflammatory bowel disease (IBD)
experience active disease and need treatment (3,4). High
disease activity is associated with an increased risk of
pregnancy complications and adverse outcomes, including
preeclampsia, preterm delivery, low birth weight, small for
gestational age, and fetal loss (5–13). Adequate disease
control during pregnancy is therefore paramount for fetal
and maternal health, as acknowledged by recent publica-
tions (6,14–16), and the risks of untreated disease during
pregnancy should be evaluated against the risks related to
drug exposure of mother and fetus. However, some treat-
ments are not used in pregnant patients, due to proven ter-
atogenicity (for example, methotrexate) or because of
concerns due to the absence of a well-established safety
profile in pregnancy (16).
Clinical trial data on the effects of drugs on preg-
nancy outcomes are sparse, since pregnant women are gen-
erally excluded from participation in clinical studies, and
women who become pregnant during a trial have treatment
stopped immediately (14). Therefore, evidence generated
through pharmacovigilance reporting and pregnancy reg-
istries is extremely important to help physicians and patients
make informed decisions regarding anti–tumor necrosis fac-
tor (anti-TNF) treatment for rheumatic diseases and CD
during pregnancy (15,17).
TheUCBPharma safety database contained reports
of 625 pregnancies exposed to certolizumab pegol (CZP)
up to 2014 (18), while the 2017 data cutoff presented here
includes 1,600 CZP-exposed pregnancies. With a substan-
tial number of pregnant patients now being exposed to
CZP across the different indications, more data are avail-
able to gain a better understanding of the timing of gesta-
tional exposure and its impact on maternal and infant
health. In particular, exposure during the first trimester,
when most organogenesis takes place, is of interest. The
objective of our investigation is to provide information on
pregnancy outcomes, includingmajor congenital malforma-
tions and other adversematernal and fetal outcomes, with a
specific focus on the timing of CZPexposure.
PATIENTS AND METHODS
The methodology of pregnancy data collection and analy-
sis has been described previously (18). Reports of CZP-exposed
pregnancies were obtained from the UCB Pharma safety data-
base from the start of CZP clinical development through the cut-
off date of March 6, 2017. We report the totality of the data up
Figure 1. Overview of pregnancies exposed to certolizumab pegol (CZP). Eleven patients were included in more than 1 treatment indication cate-
gory (rheumatic diseases, Crohn’s disease, or other) due to multiple reported indications. RA = rheumatoid arthritis; AS = ankylosing spondylitis;
axSpA = axial spondyloarthritis; PsA = psoriatic arthritis; JIA = juvenile idiopathic arthritis.
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to the cutoff date, including those given in the previous data cut
(18). Information on pregnancy dating, CZP exposure, congenital
malformations, and other pregnancy outcomes, maternal comor-
bidities, and concomitant medications was extracted.
Pregnancies were classified as prospective or retrospec-
tive (19). Prospective pregnancies were those that were
reported to UCB Pharma while ongoing and for which no fetal
abnormalities were known. In contrast, pregnancies whose out-
comes (including abnormal ultrasound results) were already
known at initial notification were categorized as retrospective.
The focus of this analysis was on prospectively reported preg-
nancies to avoid potential bias in outcome reporting rates.
Pregnancy outcomes were categorized as follows: live
birth, miscarriage (non-induced embryonic or fetal death or pas-
sage of products of conception before 20 weeks of gestation),
induced abortion (medically indicated or elective), and stillbirth
(a fetal death occurring at or after 20 weeks of gestation). Ongo-
ing pregnancies included any pregnancy with an estimated (or
calculated) due date less than 3 months before the cutoff date of
March 6, 2017. If no information on pregnancy outcome was
available after 3 months following the estimated pregnancy due
date, it was considered lost to follow-up and reported as having
an unknown outcome.
Trimesters of pregnancy were defined by time since the
first day of the last menstrual period (LMP) and distinguished as
first (up to 12 weeks and 6 days’ gestation), second (13–28 weeks
and 6 days’ gestation), and third (any time at or after 29 weeks’
gestation) (20). Timing of CZP exposure during pregnancy was
categorized into first, second, and third trimester by entering the
exposure start, stop, and restart dates (where applicable) into an
algorithm when sufficient data regarding the LMP were available.
Live birth characteristics of infants analyzed included the
gestational age at delivery (i.e., the number of completed weeks
starting from LMP), low birth weight (≤2,500 gm), small for ges-
tational age (a birth weight less than the tenth percentile for
infants of the same gestational age and sex), and prematurity (in-
fants born before 37 weeks’ gestation). Mothers’ indications,
comorbidities, adverse events, and concomitant medications were
also analyzed.
Information on mother and infant was recorded in
Council for International Organization of Medical Sciences
forms for cases of major congenital malformations, which were
reviewed by a clinical teratologist. The clinical review assessed
the presence and characterization of malformations among live-
born infants and the possible temporal association between mal-
formation, organogenesis, and medication exposure.
RESULTS
Overview of pregnancies. A total of 1,600 reports
of CZP-exposed pregnancies were entered in the UCB
Pharma safety database from the start of CZP clinical
development (earliest report July 12, 2001) through March
6, 2017, with 1,541 maternal and 59 paternal CZP expo-
sures (Figure 1). The majority (n = 1,137) of pregnancies
Table 1. Maternal demographics by indication for CZP use in prospectively reported pregnancies with maternal CZP
exposure*
Known outcomes
Unknown outcomes
(n = 411)§
Total
(n = 528)†
Rheumatic diseases
(n = 301)‡
CD
(n = 195)
Report source
Spontaneous reports¶ 245 (46.4) 125 (41.5) 97 (49.7) 378 (92.0)
Clinical trials 65 (12.3) 37 (12.3) 21 (10.8) 7 (1.7)
NIS/OLEs/compassionate use# 218 (41.3) 139 (46.2) 77 (39.5) 17 (4.1)
Region
North America 317 (60.0) 129 (42.9) 171 (87.7) 289 (70.3)
Europe 119 (22.5) 85 (28.2) 22 (11.3) 84 (20.4)
Asia 62 (11.7) 61 (20.3) 0 (0.0) 14 (3.4)
Latin America 9 (1.7) 8 (2.7) 0 (0.0) 6 (1.5)
Middle East 11 (2.1) 10 (3.3) 0 (0.0) 7 (1.7)
Australia/New Zealand 9 (1.7) 8 (2.7) 1 (0.5) 8 (2.0)
Africa 1 (0.2) 0 (0.0) 1 (0.5) 0 (0.0)
Maternal age at EDD
Number with available data 455 254 178 200
18–34 years 332 (73.0) 169 (66.5) 146 (82.0) 154 (77.0)
<18 years 1 (0.2) 1 (0.4) 0 (0.0) 2 (1.0)
≥35 years 122 (26.8) 84 (33.1) 32 (18.0) 44 (22.0)
Median (range) years 31 (17–44) 32 (17–44) 30 (18–43) 30 (16–55)
* Except where indicated otherwise, values are the number (%). CD = Crohn’s disease; NIS = non-interventional studies;
OLEs = open-label extension studies; EDD = estimated due date.
† Includes pregnancy reports where the indication for treatment of the mother with certolizumab pegol (CZP) was unknown
(n = 43) and excludes 11 pregnancies where more than 1 indication was reported.
‡ Includes rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis, psoriatic arthritis, and juvenile idiopathic arthritis.
§ Includes pregnancy reports where the indication for treatment (n = 50), report source (n = 9), and region (n = 3) were
unknown.
¶ Including registries (but excluding Organization of Teratology Information Services), social media reports, and reports from
the literature.
# Includes healthy volunteers.
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with maternal exposure were prospective. Outcomes were
known for 528 prospective pregnancies with maternal CZP
exposure, which included 10 twin pregnancies; 198
prospective pregnancies were ongoing at the time of data
cutoff (Figure 1). The outcome was not known for 411
cases.
The main indications of women with CZP expo-
sure and known prospective pregnancy outcomes were
rheumatic diseases (n = 301) and CD (n = 195). Rheu-
matic diseases included RA (n = 235), ankylosing spon-
dylitis/axial SpA (n = 45), PsA (n = 18), and juvenile
idiopathic arthritis (n = 5) (Figure 1). Of note, with regard
to indications for treatment, 11 patients were counted
more than once due to multiple reported indications.
Prospective pregnancies. Maternal demographics.
Almost half (46.4%) of prospective pregnancies with
maternal CZP exposure and known outcomes were spon-
taneous reports (including those found in the literature);
the remaining 53.2% of reports came from other sources,
with interventional clinical trials accounting for 12.3% of
pregnancy reports (Table 1). The majority of pregnancy
reports originated from North America (60.0%) and Eu-
rope (22.5%). The median age at the estimated due date
(EDD) was 31 years (range 17–44 years), with 26.8% of
women age 35 years or older (Table 1). Of the women
with CD, 87.7% were in North America, compared to
42.9% of those with rheumatic diseases (Table 1). Of
note, more women with rheumatic diseases (33.1%) than
with CD (18.0%) were older than 35 years at EDD
(Table 1). The maternal demographics of prospective
pregnancies with unknown outcome were also reviewed
for comparison. These reports originated almost exclu-
sively from spontaneous reporting (Table 1). Of note, the
mother’s age was reported for only 50% of these patients
(Table 1).
Pregnancy outcomes and CZP exposure. A total of
528 pregnancies (including 10 twin pregnancies) had 538
known outcomes: 452 pregnancies resulted in 459 live
births (85.3% of 538), and there were 47 miscarriages
(8.7% of 538), 27 elective abortions (5.0% of 538), and 5
stillbirths (0.9% of 538) (Figure 2). Analysis of pregnancy
outcomes demonstrated similar trends for women with
rheumatic diseases and those with CD: live births were
the most common pregnancy outcome in both indications
(Figure 2). Of note, 2 cases of neonatal death were
reported: 1 member of a female twin pair (born at 25
weeks), from brain damage and pneumoperitoneum; and
1 member of a female twin pair (born at 27 weeks) with a
Figure 2. Known outcomes for prospectively reported pregnancies with maternal exposure to certolizumab pegol. Ten twin pregnancies are
included in the total number of pregnancy outcomes (4 in mothers with rheumatic diseases, 5 in mothers with Crohn’s disease [CD], and 1 in a
mother with unknown indication). Miscarriage was defined as embryonic or fetal death before 20 weeks of gestation. Induced abortion includes
both elective and medically indicated abortions.
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heart defect who developed an unspecified infection of
the intestines ~8 weeks after birth and underwent surgery.
The infant did not survive the surgery.
Serious maternal infections occurred in 22 (4.2%)
of 528 prospective pregnancies. For the 452 CZP-exposed
women whose prospective pregnancies resulted in a live
birth, maternal comorbidities included preeclampsia (in 5
patients [1.1%]) and gestational diabetes (in 6 patients
[1.3%]).
Maternal exposure to CZP occurred during at
least the first trimester for 367 (81.2%) of the 452
prospective pregnancies resulting in a live birth, including
132 (29.2%) exposed during the first trimester only
(Figure 3A). CZP exposure during all 3 trimesters of
pregnancy was reported by 201 pregnant women with a
live birth outcome (44.5%) (Figure 3A). Over half of the
pregnant women with CD who had live births (55.6%)
were exposed to CZP during all 3 trimesters, compared to
37.1% of those with rheumatic diseases (Figure 3B).
More women with rheumatic diseases than women with
CD were exposed to CZP during the first trimester only
or during the first and second trimesters (Figure 3B),
reflecting the differing clinical practice between the treat-
ment of CD and the treatment of rheumatic diseases.
Concomitant medications were reported for only
382 pregnancies, and the type of medication was unspecified
Figure 3. Trimesters of maternal certolizumab pegol (CZP) exposure for prospectively reported pregnancies resulting in a live birth. A, Timing of
CZP exposure for all pregnancies. A total of 452 pregnancies resulted in a live birth, including those in which the mother was exposed preconcep-
tion (n = 5; CZP exposure stopped >14 days and ≤70 days prior to the first trimester) and pregnancies for which the timing of exposure could not
be determined (n = 8), as well as 1 patient exposed in the first and third trimesters. Black, dark gray, and light gray shading represent CZP expo-
sure during the first, second, and third trimesters, respectively; shading gradients reflect exposure during multiple trimesters. B, Exposure by indi-
cation for CZP use. There were 8 live births for which the timing of exposure could not be determined (n = 2 for patients with rheumatic disease
and n = 6 for patients with Crohn’s disease).
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for 3 of those pregnancies. Nonsteroidal antiinflammatory
drugs and steroids were the most frequent medications used;
7 miscarriages were reported in patients who received con-
comitant methotrexate.
Live birth characteristics. Among women with CZP
exposure, 452 prospective pregnancies resulted in 459 live
births; 17 infants from 10 twin pregnancies were reported.
Four twin pregnancies occurred in women with rheumatic
diseases and 5 in women with CD. The indication of 1
mother of twins was unknown. Among the singleton live
births, 31.4% of women had a cesarean section (24.2% of
women with rheumatic diseases and 42.7% of women with
CD) (Table 2). Of the live births, 11.9% were preterm,
with similar proportions in the different indications; the
median gestational age at birth was 39 weeks (minimum
27 weeks, maximum 43 weeks) (Table 2). Twenty-four
(11.7%) of 205 infants had low birth weight (Table 2); no
differences were observed between infants of mothers
with rheumatic diseases and those with CD. A low num-
ber of infants (4 [0.9%] of 442) were reported as small for
their gestational age.
Major congenital malformations. Adverse events
reported for the infants did not show any patterns or clus-
ters of events suggesting a specific safety signal in new-
borns. Major congenital malformations were reported for
8 live-born infants (1.7%): 4 infants of mothers with RA, 1
infant of a mother with axial SpA, and 3 infants of mothers
with CD (Table 3). Except for the mothers of the infants
with cerebral ventricle dilatation, congenital heart disease,
and hydronephrosis, all mothers of the infants with major
congenital malformations were exposed to CZP at least
during the first trimester. The women who had infants with
accessory auricle and polydactyly were exposed during all
3 trimesters of their pregnancies (Table 3).
No discernible patterns of birth defects among the
CZP-exposed infants were observed. The teratologist review
concluded no temporal association with CZP exposure for
the case of hydronephrosis, owing to evidence of anomalies
on ultrasound prior to the initiation of medication (during
the third trimester). The possibility of an association could
not be ruled out for the cases of anal fistula, accessory auri-
cle, vesicoureteric reflux, talipes, and congenital heart dis-
ease. It was not possible to assess temporality for the
cerebral ventricle dilatation. It should be noted that a famil-
ial predisposition was present for the infant born with poly-
dactyly: the father, the father’s sister, and the paternal
grandmother all had the same malformation at birth.
DISCUSSION
The large majority (85.3%) of CZP-exposed
pregnancies evaluated in this analysis resulted in live
births, and the rate of major congenital malformations for
Table 2. Characteristics of live-born singletons from prospectively
reported pregnancies with maternal exposure to CZP*
Characteristic
All
(n = 442)†
Rheumatic
diseases
(n = 252)‡
CD
(n = 164)‡
Cesarean section 139 (31.4) 61 (24.2) 70 (42.7)
Gestational age at birth
Number with available
data
326 195 120
20 to <32 weeks 4 (1.2) 1 (0.5) 2 (1.7)
32 to <37 weeks 35 (10.7) 22 (11.3) 12 (10.0)
≥37 weeks 287 (88.0) 172 (88.2) 106 (88.3)
Median (range) weeks 39 (27–43) 39 (27–43) 39 (31–42)
Birth weight
Number with available
data
205 145 55
Low birth weight§ 24 (11.7) 17 (11.7) 7 (12.7)
* Except where indicated otherwise, values are the number (%). Of 442
singleton infants, 4 (0.9%) were small for gestational age (2 [0.8%] of
252 born to mothers with rheumatic diseases and 2 [1.2%] of 164 born
to mothers with Crohn’s disease [CD]). CZP = certolizumab pegol.
† Includes patients with multiple and unknown indications.
‡ Includes patients who had both rheumatic diseases and CD.
§ ≤2,500 gm.
Table 3. Major congenital malformations in live-born infants from prospectively reported pregnancies
and timing of maternal CZP exposure*
Infant abnormality
Mother’s indication
for CZP use
CZP exposure
First trimester Second trimester Third trimester
Accessory auricle RA X X X
Anal fistula RA X – –
Congenital heart disease† RA – X X
Polydactyly RA X X X
Cerebral ventricle dilatation† Axial SpA – – X
Talipes CD X – –
Vesicoureteric reflux CD X X –
Hydronephrosis CD – – X
* A total of 452 pregnancies resulted in live births. CZP = certolizumab pegol; RA = rheumatoid arthritis;
SpA = spondyloarthritis; CD = Crohn’s disease.
† Premature birth.
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CZP-exposed infants was similar to those reported for the
general population in the US and Europe (21,22). Most
pregnancies were exposed to CZP at least during the first
trimester, when organogenesis primarily occurs; 201 of
452 pregnancies resulting in a live birth were exposed dur-
ing all 3 trimesters. No discernible trends linking major
congenital malformations to the timing of CZP exposure
were observed, similar to data from other prospective
studies (23–25). The frequencies of the pregnancy-asso-
ciated comorbidities preeclampsia and gestational dia-
betes were similar to those in the general population
(26,27), and no cases of eclampsia were reported. The fre-
quency of serious infections during pregnancy was consis-
tent with that reported in CZP-exposed patients (28–31).
Our review showed that CZP treatment during all
3 trimesters of pregnancy was more common in women
with CD (55.6%) than in women with rheumatic dis-
eases (37.1%). Spontaneous disease improvement during
pregnancy is less likely in women with IBD than in women
with RA and other rheumatic diseases, and many patients
with IBD may require treatment throughout pregnancy,
thus potentially reducing the risk of adverse outcomes,
such as spontaneous miscarriage, premature birth, low
birth weight, and small for gestational age (13,32,33).
Compared to the incidence of low birth weight in the US
general population (8.1%) (34), the incidence of low birth
weight among singletons in our review (11.7%) was
slightly elevated; however, this is consistent with previous
reports for anti-TNF agents (35). Pregnancy outcomes,
gestational age, low birth weight and small size at birth,
and the rate of congenital malformations were similar for
mothers with CD and their infants, compared to mothers
with rheumatic diseases and their infants.
Despite the increasing evidence regarding the
safety of anti-TNF therapies, patients and physicians still
have concerns regarding their use during pregnancy. The
potential risks to the fetus associated with the use of drugs
during pregnancy are strongly related to the timing of
exposure. During the first trimester, drug exposure can
affect organogenesis and increase rates of miscarriage or
congenital malformations. Preconception and birth control
assessment is therefore important to provide information
regarding the safety of anti-TNF agents before and during
the time to conception, as well as during early pregnancy
(36). Until December 2017, the European Union (EU)
label advised women to take birth control measures for at
least 5 months after the last CZP administration (37). As
of January 2018, the EU label has been revised to mention
that for women planning pregnancy, contraception may be
considered, while taking into account their need for treat-
ment (38). There are no contraception recommendations
in place in the US label regarding CZP use (39), which
likely contributes to the majority of the pregnancy reports
in this review originating in North America.
This analysis of prospective pregnancy reports
from the UCB Pharma safety database represents the larg-
est published cohort of pregnant women exposed to an
anti-TNF agent for the management of chronic inflamma-
tory diseases. It addresses the need for new and detailed
studies of the impact of drug exposure during pregnancy
and supports the conclusion that exposure to CZP in
utero does not appear to increase the risk of major con-
genital malformations or fetal loss. The results are also
consistent with the growing body of evidence becoming
available on anti-TNF exposure during pregnancy, which
indicates no association with an increased risk of adverse
neonatal outcomes or congenital malformations (40).
Recent systematic reviews and meta-analyses have
found no link to adverse outcomes for pregnancies with
anti-TNF exposure during the first trimester (17,40,41),
and more encouraging data are becoming available that
support the use of these therapeutics during pregnancy
(17), helping to alleviate women’s and physicians’ con-
cerns regarding the impact of exposure. Exposure in late
pregnancy and the resulting potential risk of postnatal
infections (17) are associated with active placental drug
transfer from mother to infant, mediated by binding of
the Fc region to the neonatal Fc receptor (FcRn) (42). In
contrast to other anti-TNF agents, the CZP molecule
lacks the Fc moiety, preventing binding to placental
FcRn, thus limiting placental transport (43).
Limitations to our analysis include the fact that,
while the UCB safety database is an appropriate tool for
standard safety evaluations, the data collection process is
designed for pharmacovigilance purposes, rather than
being an analysis tool for scientific pregnancy research.
In addition, no untreated control group was available for
comparison; therefore, a formal assessment of data by
statistical analysis was not possible. However, it is
acknowledged that for studies with a focus on pregnancy,
inclusion of a control group is not always possible (44).
Uncontrolled large data sets are still of value, in particu-
lar when assessing the frequency of rare events like con-
genital malformations, since this information is readily
available for the general population for comparison.
Another limitation of this analysis is the fact that
pregnancy outcome was unknown for a third of the cases.
Missing outcomes data is an inherent issue with passive
reporting of pregnancy outcomes, despite adequate fol-
low-up attempts. In addition, the small number of avail-
able data for certain birth characteristics, such as low
birth weight, impedes drawing any definite conclusions
based on this information. Accurate and extrapolatable
rates of miscarriage are also hard to estimate from
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spontaneously reported data, since reports are received at
various times throughout gestation, with a report received
later on being at lower risk of spontaneous abortion than
a report received earlier. Furthermore, data collected via
spontaneous reporting systems are affected by reporting
bias and often associated with inherent limitations, due to
the passive and voluntary nature of the reporting systems.
To reduce bias toward the reporting of adverse outcomes
associated with retrospective data, we focused our analysis
on prospective pregnancy reports to allow a quantitative
assessment of outcomes and evaluation of the temporal
association between CZP exposure and outcomes.
The results of our analysis represent the most com-
prehensive published data set for pregnancies exposed to a
single anti-TNF agent to date, with a particular focus on
assessment of the temporal association. The fact that 528
CZP-exposed pregnancies resulted in 459 live births, with
367 women being exposed to CZP during the first tri-
mester, and that only 8 cases of major congenital malforma-
tions were reported, confirms and expands the known CZP
safety profile. Data from other sources, such as the ongoing
MotherToBaby study from the Organization of Teratology
Information Specialists (45), will provide further important
information to confirm the findings described here. How-
ever, these data are reassuring for women of childbearing
age affected by chronic inflammatory diseases who need an
anti-TNF agent to control their condition and wish to
become pregnant or are pregnant during CZP treatment.
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